Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02289248 · ClinicalTrials.gov registry record · Phase 1
Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02289248: Completed Phase 1 study, sponsored by Yale University.
NCT02289248 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02289248, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Subjects with depressive episodes will be recruited to undergo a brief 2 week course of IV infusions of ketamine in combination with cognitive behavioral therapy for 8 weeks.
Primary Outcome
Hopkins Verbal Learning Test and extinction learning tasks will be administered both one week before and 24-hours after the first ketamine infusion and the change in scores compared.
Interventions
- DRUG Ketamine
- BEHAVIORAL Cognitive Behavioral Therapy (CBT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
What the finished NCT02289248 record still lists
NCT02289248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT02289248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02289248 about?
NCT02289248 is a clinical study titled "Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine". Subjects with depressive episodes will be recruited to undergo a brief 2 week course of IV infusions of ketamine in combination with cognitive behavioral therapy for 8 weeks.
What is the current status of trial NCT02289248?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-02. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02289248?
The interventions under investigation include: Ketamine (DRUG), Cognitive Behavioral Therapy (CBT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02289248?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02289248's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia